A variety of tumors can be improved by inhibiting PD1/PD-L1, and PD-1 inhibitors Pembrolizumab and Nivolumab have been approved by the FDA for advanced melanoma and non-small cell lung cancer [110]. The gene discussed is CD274; the disease is melanoma.